Stockreport

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease [...

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 202 [Read more]